Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPAG 2015
2015-000929-37Phase 2Completed
- Sponsor
- Goelams
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) comparing Eltrombopag arm with Placebo arm (2 arms). Primary endpoint: Overall survival at 12 months. Started Aug 2015; status: completed.
02
Drugs
eltrombopag
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-000929-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000929-37.